RESEARCH

Clinical features and outcomes of adrenal schwannoma: a study of 13 cases from a single centre

Henghai Huang^{1,*}, Qijian Ding^{2,*}, Xiaocao Lin¹, Delin Li¹, Jingjing Zeng³ and Weijin Fu²¹Department of Urology, Wuzhou GongRen Hospital, Wuzhou, China²Department of Urology, The First Affiliated Hospital of GuangXi Medical University, Nanning China³Department of Pathology, The First Affiliated Hospital of GuangXi Medical University, Nanning, ChinaCorrespondence should be addressed to W Fu: fuwj66@aliyun.com

*(H Huang and Q Ding contributed equally to this work)

Abstract

Background: Adrenal schwannomas (AS) are extremely rare neoplasms. This study shares our experience regarding the diagnosis and operative management of AS.

Methods: Clinical details, radiologic, laboratory, and pathologic findings as well as follow-up data were analysed retrospectively for 13 AS patients who accepted surgery at a tertiary referral hospital in China between 1 January 1996, and 31 December 2017.

Results: The mean age of the patients at diagnosis was 44.7 ± 13.7 years (range 19–62 years; male: female ratio, 1:1.16), of whom seven patients had unilateral AS on the right side, and the remaining six on the left side. None of the cases were hormonally active. None of the 13 cases were diagnosed as AS by CT imaging before the operation. Among the patients, ten were asymptomatic. The mean preoperative size was 7.1 ± 3.2 cm (range 1.6–12.6 cm). All patients underwent surgery, with open adrenalectomy in five patients and laparoscopy in eight patients. The mean tumor size on pathologic examination was 6.8 ± 3.0 cm (range 3.0–11.7 cm). The surgical specimens were confirmed by pathological examination. During a median follow-up of 60.8 ± 17.7 months, no patients showed recurrence or metastasis.

Conclusion: The preoperative diagnosis of AS remains difficult despite the advances in imaging examinations. After complete resection, the prognosis of AS is excellent.

Key Words

- ▶ adrenal schwannoma
- ▶ clinical features
- ▶ outcomes

Endocrine Connections
(2021) **10**, 543–549

Introduction

Schwannoma is a rare tumour arising from Schwann cells in the myelinated neural sheath of the nerves (1). Tumours can occur in various places, such as the head, neck, extremities, retroperitoneum, and psoas muscle (2, 3). Related studies have shown that approximately 5% of schwannoma cases come from the retroperitoneum (4). However, schwannomas presenting in the visceral organs, especially the adrenal glands, are rare (5, 6). The adrenal medulla is innervated by the phrenic nerve, the vagus nerve and the sympathetic trunk. Adrenal schwannoma (AS) arises from Schwann cells related to these nerves

(7, 8). AS is usually benign and slow-growing but can be malignant (9). AS is mostly asymptomatic, but some patients can present with either abdominal or flank pain. AS has a good prognosis after surgical excision.

Due to its low incidence, only a few case reports and small case series have been published to date (10). Thus, a comprehensive understanding of the clinical features, diagnosis, and clinical treatment of AS is necessary. In this study, we present our experiences regarding the clinical features, diagnostic imaging, and operative treatment of 13 AS cases in a single institution.

Subjects and methods

A total of 548 patients with adrenal neoplasms were treated at Wuzhou GongRen Hospital between 1 January 1996, and 31 December 2016. Of these, 13 (2.37%, 13/548) were pathologically diagnosed with AS. The clinicopathological features, diagnosis, surgical intervention and follow-up data of these patients were retrospectively analysed. This study was approved by the Ethics Committee of Wuzhou GongRen Hospital.

All patient demographic parameters, chief complaints, concomitant diseases and operative histories were analysed. All patients were assessed for adrenal function, including (i) serum potassium; (ii) plasma adrenocorticotrophic hormone and cortisol (08:00, 16:00 and 12:00 h); (iii) 24-h urinary free cortisol; (iv) plasma renin and aldosterone (standing and lying position); (v) 24-h urinary epinephrine, norepinephrine, dopamine and vanillylmandelic acid; (vi) serum epinephrine, norepinephrine and dopamine and (vii) serum testosterone and oestrogen.

All patients were evaluated by ultrasound and enhanced CT. The precontrast and postcontrast Hounsfield units (HU), maximum diameter, characteristics and preoperative diagnosis were analysed.

The surgical specimens were confirmed by pathological examination. The resection margins and pathological diagnosis were evaluated by two pathologists specialized in genitourinary diseases. The routine follow-up schedule was every 3 months in the 1st year after surgery, every 6 months in the 2nd year postoperatively, and once each year in the future.

Results

Table 1 summarizes the essential demographic characteristics and clinical presentations of the 13 AS patients. Their mean

age was 44.7 ± 13.7 years (range, 19–62 years), including six patients with tumours on the left and seven on the right. Ten cases were detected incidentally; two patients presented with abdominal or back discomfort, and one patient presented with dizziness. Table 1 summarizes their demographic characteristics and clinical manifestations. Preoperative endocrine function examinations and serum potassium levels were normal in Table 2. A routine medical examination was the main indicator (10/13; 76.9%) of clinical signs leading to the discovery of an AS.

All of the adrenal masses were unilateral. Ultrasonography was performed in 13 patients but showed no specificity. The masses showed solid or mixed echoes. Blood flow signals could be observed in the tumours, and the masses were hypoechoic, with regular morphology and clear boundaries. A small amount of blood flow was observed within or around the lesions.

In our study, CT findings were available for 13 patients. Table 3 summarizes the clinical and CT findings of the 13 AS patients. Six tumours were located on the left adrenal gland, and the remaining seven were on the right side. The tumour diameters ranged from approximately 1.6 to 12.6 cm (mean 7.1 ± 3.2 cm). All tumours were unilateral, heterogeneous, round or oval solitary encapsulated masses and thus presented with well-circumscribed margins in the unenhanced phase (Figs 1, 2 and 3). Intratumoural cystic changes were observed in six cases (46.2%, Fig. 1), calcification was observed in one case (7.7%, Fig. 2), and septa were observed in three cases (23%, Fig. 3). Haemorrhage was not observed in any of the cases.

On the multiphase CT images, all solid areas displayed an early mild heterogeneous enhancement in the hepatic arterial phase and a delayed progressive enhancement in the portal venous and equilibrium phases. There were no malignant features, such as invasion of the adjacent tissues, regional lymph node involvement, or distant metastasis. None of the 13 patients were diagnosed with AS by CT imaging before their operation. The preoperative radiologic studies suggested that five were inconclusive, one was considered to be malignant ('adrenal carcinoma' or 'liposarcoma'), four were considered to be pheochromocytomas, two were considered to be cortical adenomas, and one was considered to be a cyst. A retrospective review revealed that tumour density was heterogeneous with low attenuation in 12 patients and homogeneous in 1 patient, as shown in the precontrast CT images. Slight, early enhancement was seen in the postcontrast images in all of the patients.

All of the AS patients underwent operative resection by open adrenalectomy (five patients) and laparoscopy

Table 1 Patients' demographic and clinical characteristics.

Patients	n (%)
Age, median (range)	44.7 (19–62)
Gender	
Female	7 (7/13)
Male	6 (6/13)
Clinical presentations	
Incidental	10 (10/13)
Abdominal/back discomfort	2 (2/13)
Dizziness	1 (1/13)
Tumor site	
Right	7 (7/13)
Left	6 (6/13)
Mean preoperative tumor size in cm (range)	7.1 (1.6–12.6)
Mean tumor size in cm on pathology (range)	6.8 (3.0–11.7)

Table 2 Preoperative endocrine function examinations in 13 patients.

Case/ sex	Renin (pg/mL)		ALD (pg/mL)		Potassium (mmol/L)	ACTH (pg/mL)		Cortisol (nmol/L)			UFC (nmol/24 h)	VMA (μmol/24 h)	DA (μg/24 h)	E (μg/24 h)	NE (μg/24 h)
	O	R	O	R	(3.5–5.3)	08:00 h (7.2–63.3)	16:00 h	08:00 h (185–624)	16:00 h (107–333)	12:00 h	(108–961)	(< 68.6)	(93.2–470.3)	(1.5–34.5)	(22.1–75.3)
Normal range	2.8–28 pg/mL	1.8–24.5 pg/mL	70–300 pg/mL	30–160 pg/mL	3.5–5.3 mmol/L	7.2–63.3 pg/mL	16:00 h	08:00 h (185–624)	16:00 h (107–333)	12:00 h	(108–961)	(< 68.6)	(93.2–470.3)	(1.5–34.5)	(22.1–75.3)
1/F	10	7	153	110	3.7	45	25	482	260	141	156	17	123	8	23
2/F	8	4	147	98	4.0	48	29	490	255	133	174	14	145	14	34
3/M	7	5	138	88	3.9	38	22	404	209	111	155	19	210	12	45
4/F	12	8	229	162	4.9	55	32	580	301	139	199	22	228	19	30
5/F	7	4	92	69	5.0	28	16	277	134	110	121	30	165	20	49
6/M	19	15	201	141	4.2	63	35	635	300	129	211	26	213	16	31
7/M	15	11	191	138	4.1	58	29	598	288	157	183	33	111	9	57
8/M	15	9	205	145	3.6	52	25	555	283	144	177	31	238	32	68
9/F	10	6	177	129	3.9	57	30	602	319	131	209	19	199	23	55
10/M	17	10	200	147	4.7	60	33	618	299	187	189	11	376	25	34
11/F	6	3	82	55	4.9	27	15	259	138	110	135	29	288	28	65
12/F	6	4	78	56	3.8	31	17	287	164	125	122	25	159	15	34
13/M	17	12	181	126	4.5	44	20	483	251	139	163	26	231	18	39

ACTH, adrenocorticotrophic hormone; ALD, aldosterone; R, orthostatic; E, epinephrine; DA, dopamine; NE, norepinephrine; UFC, 24-h urinary free cortisol; VMA, vanilmandelic acid.

(the remaining eight patients). Surgical indications were ≥ 1 of each of the following: tumour size ≥ 4 cm ($n=11$), suspicious appearance on imaging ($n=5$), or a patient's fear of malignancy ($n=9$).

The mean tumour size on pathologic examination was 6.8 ± 3.0 cm (range 3.0–11.7 cm). The tumour was typically well-circumscribed as an encapsulated round (Fig. 4A) or lobulated mass (Fig. 4C). The cut surface often consisted of firm yellow-tan tissue (Fig. 4B) or contained cystic or solid regions (Fig. 4D). All 13 patients were diagnosed with AS by pathology. Microscopic examination showed that the tumour consisted of alternating hypercellular (Antoni type A tissue) and hypocellular areas (Antoni type B tissue) (Fig. 5A and B). Immunohistochemical staining showed a diffuse expression of S-100 protein (Fig. 5C) and positive immunoreactivity for vimentin (Fig. 5D) in the tumour cells. These findings are consistent with a diagnosis of benign AS.

There was no mortality, minor morbidity or complication in our patients. During a median follow-up of 60.8 ± 17.7 months (range 39–92 months), no patient had recurrence or metastasis.

Discussion

AS is a rare incidentaloma found in the adrenal medulla, and fewer than 100 cases have been reported to date (6, 10, 11, 12, 13, 14, 15, 16, 17, 18). The vast majority of AS patients are sporadic. The specific cause of the disease is unknown. Genomic analysis demonstrated that there were neurofibromatosis type 2 (NF2) alterations in intracranial and spinal schwannoma, which may be related to chromosome 22q and NF2 mutations. The chromatin-modifying genes ARID1A or ARID1B, as well as mutations in DDR1 were found in intracranial and spinal schwannoma (19, 20). However, it remains to be investigated whether similar genetic changes also exist in AS patients. The ratio of female to male patients is approximately 1.2:1, and the mean age of onset is 49 years (6). In this study, the ratio of female to male patients was approximately 1.16:1, and the mean age was 44.7 years, which is consistent with the literatures. Furthermore, the majority of cases were likely isolated; therefore, the true incidence of AS in patients undergoing adrenalectomy remains unknown. In this study, the incidence of AS among these patients was 2.37% (13/548) at our institution.

Owing to the lack of endocrine function, most cases of AS do not cause any corresponding clinical symptoms.

Table 3 Clinical and CT findings in 13 patients with adrenal schwannomas.

Case/sex/age	Side	Clinical presentations	Diameter (cm)	Morphology	Margin	Cystic	Calcification	Septa
1/F/44	R	Asymptomatic	9.9	Rounded	Well-circumscribed	-	-	+
2/F/19	R	Asymptomatic	3.9	Rounded	Well-circumscribed	-	-	+
3/M/40	L	Asymptomatic	5.86	Rounded	Well-circumscribed	+	+	-
4/F/59	R	Asymptomatic	4.5	Rounded	Well-circumscribed	-	-	-
5/F/27	L	Abdominal/back discomfort	8	Rounded	Well-circumscribed	+	-	-
6/M/24	R	Asymptomatic	6.06	Oval	Well-circumscribed	+	-	-
7/M/51	L	Asymptomatic	4.48	Rounded	Well-circumscribed	-	-	-
8/M/62	R	Dizziness	12.62	Oval	Well-circumscribed	+	-	-
9/F/57	R	Asymptomatic	10.12	Rounded	Well-circumscribed	-	-	-
10/M/47	L	Asymptomatic	1.64	Rounded	Well-circumscribed	-	-	-
11/F/46	L	Abdominal/back discomfort	5.98	Rounded	Well-circumscribed	-	-	-
12/F/53	R	Asymptomatic	7.4	Oval	Well-circumscribed	+	-	-
13/M/52	L	Asymptomatic	11.58	Rounded	Well-circumscribed	+	-	+

F, female; L, left; M, male; R, right.

The majority of our patients had no clinical symptoms. In the present study, 10 out of 13 AS cases were incidental tumours. They were diagnosed with adrenal lesions while imaging for other diseases. Some patients suffer from abdominal pain and abdominal distention due to increased tumour sizes. The literature indicates that AS ranges in size from 0.6 to 14.5 cm, with a median of 5.5 cm (6). The mean tumour size in our study was 6.8 cm, which is larger than that reported in the literature and is possibly related to the late presentation of the patients to our institution.

It is difficult to diagnose AS before surgery. Imaging findings have some significance for AS diagnosis. The literature has suggested that the following signs may support the diagnosis of this entity: a nonlipid-containing mass, a well-defined border, a unilateral mass with cystic or haemorrhagic degeneration, septa with delayed enhancement and a characteristic progressive contrast enhancement pattern of the solid portions (21).

The final diagnosis of AS depends on histopathology. The typical features are as follows: (i) in gross specimens, the lesion size varies, with a round or nodular contour, with a tan-yellow to greyish-white appearance and integrated capsule, the colour of cross sections is pink or brownish-grey and slightly transparent, with a solid and rough texture and a spiral structure, and focal jelly like necrosis is visible in some specimens; (ii) by HE staining, spindle cells can be found and may be complicated by haemorrhage, cystic, and hyaline degeneration. In light of the cell arrangement, pathology can be classified as

Figure 1

Unenhanced phase (A), hepatic arterial phase (B), portal venous phase (C) and coronal CT (D). CT imaging reveals a well-circumscribed mixed solid cystic mass (red arrow) located in the region of the right adrenal gland.

Figure 2

Unenhanced phase (A), hepatic arterial phase (B), portal venous phase (C) and coronal CT (D). CT imaging reveals a well-circumscribed, heterogeneous mass with calcification (red arrow) located in the region of the left adrenal gland.

either Antoni A or Antoni B. Antoni A-type tumours show spindle cells arranged in a dense (hypercellular) manner with ill-defined intercellular spaces, and Antoni B-type tumour cells are arranged in a loose (hypocellular) manner with large intercellular spaces and a high degree of myxoid degeneration and (iii) by immunohistochemistry, specimens are always positive for the expression of S-100, Leu7, laminin, and myelin basic protein. Tumour cells can express CD34, glial fibrillary acidic protein, and cytokeratins but not epithelial membrane antigen (EMA), desmin, or actin (16). Haemorrhage, necrosis, and cystic and hyaline degeneration are thought to be indicative of

Figure 3

Unenhanced phase (A), hepatic arterial phase (B), portal venous phase (C) and coronal CT (D). CT imaging reveals a well-circumscribed, heterogeneous mass with septa (red arrow) located in the region of the left adrenal gland.

Figure 4

Gross specimen showing that the tumour is typically well circumscribed as an encapsulated round (A) or lobulated mass (C). The cut surface often consists of firm yellow-tan tissue (B) or contains areas of cyst-solid formation (D).

malignancy potential due to vascular insufficiency caused by increasing tumour size.

Most cases of AS have no endocrine function. However, a few studies have reported that AS may be accompanied by excessive secretion of corticosteroids or adrenomedullary hormones (9). It has been suggested that a routine examination of adrenal endocrine function be performed before surgery to determine the nature of the incidental adrenal tumours, to determine whether there is endocrine function and to select appropriate treatment methods.

Figure 5

Microscopic examination showing that the tumour consists of compact or loose interlacing fascicles of bland spindle cells (A, ×100). Antoni A areas (#) and loose myxoid degenerative Antoni B areas (*) are noted (B, ×200). Immunohistochemical staining demonstrates that the tumour is positive for S-100 protein (C) and vimentin (D).

The treatment of adrenal incidentaloma depends on its endocrine function and whether the tumour is benign or malignant, and it must take into account the patient's general condition and wishes. For nonfunctional adrenal incidentalomas, there is a disagreement on management. At present, the literature holds that when the diameter of the tumour is > 4 cm, the risk of malignancy increases and the risk of malignancy is >25% for tumours > 6 cm; thus, active surgical treatment is advocated. Follow-up is recommended for tumours < 4 cm. Surgical intervention is also recommended for tumours with rapid growth, inhomogeneity, an irregular shape, necrosis and invasion of adjacent structures, which may indicate malignant tumours (22, 23, 24).

Surgical resection is the most effective treatment for AS. Laparoscopic adrenalectomy is considered the gold standard technique for the treatment of benign small- and medium-sized adrenal masses (<6 cm) due to its low morbidity rate, short hospitalization and rapid patient recovery (25, 26, 27). With the development of more advanced laparoscopic equipment and technology, it has been reported that large tumours (>10 cm) have been successfully removed by laparoscopic surgery (28). Due to magnification, laparoscopic surgery requires less space, is much clearer and is more precise. A large tumour diameter is not a contraindication for laparoscopic surgery. Most Chinese urologists prefer retroperitoneal laparoscopic adrenalectomy to treat adrenal tumours (tumour size < 6 cm). However, as the size of the adrenal tumour increases, the technical difficulty increases, and there is an increased risk of dealing with malignant gland pathology. Therefore, open surgery may be a good choice for patients with tumour sizes > 6 cm. Specific operation patterns are performed according to the patient's situation and the surgeon's preference and technical expertise. In the present study, eight patients underwent retroperitoneal laparoscopic adrenalectomy (the tumour diameter of these eight cases was <6 cm). Open surgery was performed in five patients with tumour sizes > 6 cm.

It should be pointed out that if the preoperative tumor volume is large and malignancy is suspected before surgery. Open surgery should still be considered the standard surgical management of adrenal malignancy. Laparoscopic surgery can offer a shorter hospital stay and possibly a faster recovery. Therefore, this minimally invasive approach can certainly play an important role in this setting, but it should be only offered in carefully selected cases, and performed by skilled experts, to afford a better oncological outcome (29, 30). Either open surgery or laparoscopic

surgery should be chosen to avoid damaging the tumour capsule to cause tumour implantation metastasis. At that time, open surgery should be the best choice.

All patients were discharged without complications postoperatively. All patients were followed-up for a mean of 60.8 ± 17.7 months (range 39–92 months) without recurrence or metastasis. AS has a good prognosis. Although the majority of the literatures consider this disease to be benign, and our findings also confirm this. The pathogenesis of AS need to be further investigated. Herein, we still recommend routine follow-up schedules as described above after surgery.

In conclusion, due to its rarity, AS is discovered mainly during routine medical check-ups. The preoperative diagnosis of AS remains difficult. After complete resection, the prognosis of AS patients is excellent.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

References

- Ben Moualli S, Hajri M, Ben Amna M, Kolsi K, Chebil M, Ben Jilani S, Zaouech A & Ayed M. Retroperitoneal schwannoma. Case report. *Annales d'Urologie* 2001 **35** 270–272. ([https://doi.org/10.1016/s0003-4401\(01\)00042-0](https://doi.org/10.1016/s0003-4401(01)00042-0))
- Daneshmand S, Youssefzadeh D, Chamie K, Boswell W, Wu N, Stein JP, Boyd S & Skinner DG. Benign retroperitoneal schwannoma: a case series and review of the literature. *Urology* 2003 **62** 993–997. ([https://doi.org/10.1016/s0090-4295\(03\)00792-1](https://doi.org/10.1016/s0090-4295(03)00792-1))
- Rha SE, Byun JY, Jung SE, Chun HJ, Lee HG & Lee JM. Neurogenic tumors in the abdomen: tumor types and imaging characteristics. *Radiographics* 2003 **23** 29–43. (<https://doi.org/10.1148/rg.231025050>)
- Kasperlik-Zaluska AA, Roslonowska E, Slowinska-Szrednicka J, Otto M, Cichocki A, Cwikla J, Slapa R & Eisenhofer G. 1,111 patients with adrenal incidentalomas observed at a single endocrinological center: incidence of chromaffin tumors. *Annals of the New York Academy of Sciences* 2006 **1073** 38–46. (<https://doi.org/10.1196/annals.1353.004>)
- Toutouzas KG, Tsamis D, Kekis PB, Michalopoulos NV, Flessas I, Manouras A, Zografos G & Georgios Z. Laparoscopic resection of an adrenal schwannoma. *JSLS* 2012 **16** 663–667. (<https://doi.org/10.4293/108680812X13517013316753>)
- Mohiuddin Y & Gilliland MG. Adrenal schwannoma: a rare type of adrenal incidentaloma. *Archives of Pathology and Laboratory Medicine* 2013 **137** 1009–1014. (<https://doi.org/10.5858/arpa.2012-0291-RS>)
- Korets R, Berkenblit R & Ghavamian R. Incidentally discovered adrenal schwannoma. *JSLS* 2007 **11** 113–115.
- Lau SK, Spagnolo DV & Weiss LM. Schwannoma of the adrenal gland: report incidentally discovered adrenal schwannoma of two cases. *American Journal of Surgical Pathology* 2006 **30** 630–634. (<https://doi.org/10.1097/01.pas.0000194739.80174.26>)

- 9 Hou J, Zhang L, Guo Y, Chen H & Wang W. Primary adrenal schwannoma with catecholamine hypersecretion. *Archives of Medical Science* 2016 **12** 681–683. (<https://doi.org/10.5114/aoms.2016.59942>)
- 10 Kumar S, Karthikeyan VS, Manohar CS, Sreelakshmi K & Shivalingaiah M. Adrenal schwannoma: a rare incidentaloma. *Journal of Clinical and Diagnostic Research* 2016 **10** PD01–PD02. (<https://doi.org/10.7860/JCDR/2016/20405.8265>)
- 11 Abdessater M, El Mokdad M, Gas J, Sleiman W, Coloby P & Bart S. Juxta-adrenal schwannoma presenting as a giant adrenal tumor: a case report and a literature review. *International Journal of Surgery Case Reports* 2018 **53** 132–136. (<https://doi.org/10.1016/j.ijscr.2018.10.017>)
- 12 Shivalingaiah PH, Kumar P & Bajoria S. Adrenal schwannoma treated with open adrenalectomy: a case report. *Indian Journal of Surgical Oncology* 2018 **9** 83–85. (<https://doi.org/10.1007/s13193-017-0715-5>)
- 13 Bhattar R, Tomar V, Dhakad DS & Agarwal N. Benign diaphragmatic neurilemmoma mimicking a left adrenal cyst. *Turkish Journal of Urology* 2018 **44** 87–90. (<https://doi.org/10.5152/tud.2017.26780>)
- 14 Babaya N, Makutani Y, Noso S, Hiromine Y, Ito H, Taketomo Y, Ueda K, Ushijima H, Komoike Y, Yamazaki Y, et al. Case report: schwannoma arising from the unilateral adrenal area with bilateral hyperaldosteronism. *BMC Endocrine Disorders* 2017 **17** 74. (<https://doi.org/10.1186/s12902-017-0225-z>)
- 15 Cayirli H, Tanriverdi HI, Ozguven AA, Gunsar C, Ersoy B & Kandiloglu AR. Schwannoma localized retroperitoneally in a 14-year-old boy. *Case Reports in Pediatrics* 2016 **2016** 1210874. (<https://doi.org/10.1155/2016/1210874>)
- 16 Li SQ, Zhang YS, Shi J & Li HZ. Clinical features and retroperitoneal laparoscopic resection of adrenal schwannoma in 19 patients. *Endocrine Practice* 2015 **21** 323–329. (<https://doi.org/10.4158/EP14453.OR>)
- 17 Zhou W, Zhu Y, Zhang L, Xu SY & Zhan WW. Sonographic appearances of adrenal schwannomas. *Journal of Clinical Ultrasound* 2019 **47** 3–8. (<https://doi.org/10.1002/jcu.22644>)
- 18 Xiao C, Xu B, Ye H, Yang Q, Wang L & Sun YH. Experience with adrenal schwannoma in a Chinese population of six patients. *Journal of Endocrinological Investigation* 2011 **34** 417–421. (<https://doi.org/10.1007/BF03346705>)
- 19 Havik AL, Bruland O, Myrseth E, Miletic H, Aarhus M, Knappskog PM & Lund-Johansen M. Genetic landscape of sporadic vestibular schwannoma. *Journal of Neurosurgery* 2018 **128** 911–922. (<https://doi.org/10.3171/2016.10.JNS161384>)
- 20 Agnihotri S, Jalali S, Wilson MR, Danesh A, Li M, Klironomos G, Krieger JR, Mansouri A, Khan O, Mamatjan Y, et al. The genomic landscape of schwannoma. *Nature Genetics* 2016 **48** 1339–1348. (<https://doi.org/10.1038/ng.3688>)
- 21 Tang W, Yu XR, Zhou LP, Gao HB, Wang QF & Peng WJ. Adrenal schwannoma: CT, MR manifestations and pathological correlation. *Clinical Hemorheology and Microcirculation* 2018 **68** 401–412. (<https://doi.org/10.3233/CH-170316>)
- 22 Lau J, Balk E, Rothberg M, Ioannidis JP, DeVine D, Chew P, Kupelnick B & Miller K. Management of clinically inapparent adrenal mass. *Evidence Reports/Technology Assessments* 2002 **56** 1–5. (available at: <https://www.ncbi.nlm.nih.gov/books/NBK36558/>)
- 23 Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y & Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. *Endocrine Reviews* 2004 **25** 309–340. (<https://doi.org/10.1210/er.2002-0031>)
- 24 Anagnostis P, Karagiannis A, Tziomalos K, Kakafika AI, Athyros VG & Mikhailidis DP. Adrenal incidentaloma: a diagnostic challenge. *Hormones* 2009 **8** 163–184. (<https://doi.org/10.14310/horm.2002.1233>)
- 25 Erbil Y, Barbaros U, Karaman G, Bozboru A & Ozarmagan S. The change in the principle of performing laparoscopic adrenalectomy from small to large masses. *International Journal of Surgery* 2009 **7** 266–271. (<https://doi.org/10.1016/j.ijso.2009.04.011>)
- 26 Agrusa A, Romano G, Frazzetta G, Chianetta D, Sorce V, Di Buono G & Gulotta G. Laparoscopic adrenalectomy for large adrenal masses: single team experience. *International Journal of Surgery* 2014 **12** (Supplement 1) S72–S74. (<https://doi.org/10.1016/j.ijso.2014.05.050>)
- 27 Conzo G, Gambardella C, Candela G, Sanguinetti A, Polistena A, Clarizia G, Patrone R, Di Capua F, Offi C, Musella M, et al. Single center experience with laparoscopic adrenalectomy on a large clinical series. *BMC Surgery* 2018 **18** 2. (<https://doi.org/10.1186/s12893-017-0333-8>)
- 28 Brandao LF, Autorino R, Laydner H, Haber GP, Ouzaid I, De Sio M, Perdona S, Stein RJ, Porpiglia F & Kaouk JH. Robotic versus laparoscopic adrenalectomy: a systematic review and meta-analysis. *European Urology* 2014 **65** 1154–1161. (<https://doi.org/10.1016/j.eururo.2013.09.021>)
- 29 Autorino R, Bove P, De Sio M, Miano R, Micali S, Cindolo L, Greco F, Nicholas J, Fiori C, Bianchi G, et al. Open versus laparoscopic adrenalectomy for adrenocortical carcinoma: a meta-analysis of surgical and oncological outcomes. *Annals of Surgical Oncology* 2016 **23** 1195–1202. (<https://doi.org/10.1245/s10434-015-4900-x>)
- 30 Hu X, Yang WX, Shao YX, Dou WC, Xiong SC & Li X. Minimally invasive versus open adrenalectomy in patients with adrenocortical carcinoma: a meta-analysis. *Annals of Surgical Oncology* 2020 **27** 3858–3869. (<https://doi.org/10.1245/s10434-020-08454-1>)

Received in final form 21 April 2021

Accepted 28 April 2021

Accepted Manuscript published online 28 April 2021